2025 Latin America Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report
Description
The 2025 Latin America Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in Amyotrophic Lateral Sclerosis (ALS) treatment in Latin America are Mitsubishi Tanabe Pharma Corporation, Biogen Inc., BrainStorm Cell Therapeutics Inc., and Amylyx Pharmaceuticals. Mitsubishi Tanabe Pharma has notably launched Radicava® (edaravone) in Brazil, marking a significant regional presence. Biogen is recognized for QALSODY, the first therapy targeting genetic SOD1-ALS, and maintains a strong influence due to its innovative neurological treatments. BrainStorm focuses on stem cell therapies, and Amylyx Pharmaceuticals is advancing novel disease-modifying drugs, further strengthening the therapeutic landscape in Latin America.
These companies benefit from growing ALS awareness, healthcare digitization, and public-private partnerships in Latin America, particularly in Brazil, where approximately 12,000 new ALS cases are diagnosed annually. Efforts to harmonize regulatory standards across Latin American countries facilitate faster market entry for innovative treatments. Together, these four firms dominate the ALS treatment market segment through ongoing research, product launches, strategic licensing, and clinical trials, driving improved patient access to both traditional and cutting-edge therapies across the region.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in Amyotrophic Lateral Sclerosis (ALS) treatment in Latin America are Mitsubishi Tanabe Pharma Corporation, Biogen Inc., BrainStorm Cell Therapeutics Inc., and Amylyx Pharmaceuticals. Mitsubishi Tanabe Pharma has notably launched Radicava® (edaravone) in Brazil, marking a significant regional presence. Biogen is recognized for QALSODY, the first therapy targeting genetic SOD1-ALS, and maintains a strong influence due to its innovative neurological treatments. BrainStorm focuses on stem cell therapies, and Amylyx Pharmaceuticals is advancing novel disease-modifying drugs, further strengthening the therapeutic landscape in Latin America.
These companies benefit from growing ALS awareness, healthcare digitization, and public-private partnerships in Latin America, particularly in Brazil, where approximately 12,000 new ALS cases are diagnosed annually. Efforts to harmonize regulatory standards across Latin American countries facilitate faster market entry for innovative treatments. Together, these four firms dominate the ALS treatment market segment through ongoing research, product launches, strategic licensing, and clinical trials, driving improved patient access to both traditional and cutting-edge therapies across the region.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
